The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice

J Physiol Paris. 1998 Jun-Aug;92(3-4):299-303. doi: 10.1016/s0928-4257(98)80037-5.

Abstract

Apolipoprotein E (apoE)-deficient and control mice were treated chronically with either the acetylcholinesterase (AChE) inhibitor ENA713, or the M1 muscarinic agonist AF150(S). Both treatments reversed the spatial working memory impairment of apoE-deficient mice but they differed in their effects on the levels of brain AChE activity. AF150(S) enhanced the brain AChE activity of apoE-deficient mice and rendered it similar to that of the untreated controls, whereas ENA713 reduced the brain AChE activity of control mice but had no effect on that of apoE-deficient mice. These findings suggest that AChE inhibition and M1 muscarinic activation have similar beneficial cognitive effects on apoE-deficient mice, but that the cellular and molecular mechanisms underlying these effects differ.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency*
  • Carbamates / pharmacology*
  • Cholinesterase Inhibitors / pharmacology*
  • Cognition / drug effects*
  • Drug Evaluation, Preclinical
  • Histocytochemistry
  • Maze Learning / drug effects
  • Mice
  • Mice, Inbred C57BL
  • Muscarinic Agonists / pharmacology*
  • Phenylcarbamates*
  • Piperidines / pharmacology*
  • Rivastigmine
  • Thiazoles / pharmacology*

Substances

  • 1-methylpiperidine-4-spiro-(2'-methylthiazoline)
  • Apolipoproteins E
  • Carbamates
  • Cholinesterase Inhibitors
  • Muscarinic Agonists
  • Phenylcarbamates
  • Piperidines
  • Thiazoles
  • Rivastigmine